Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Ortho launches second COVID-19 antibody test

May 2020—Ortho Clinical Diagnostics announced the FDA granted emergency use authorization to its second COVID-19 antibody test—the Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Test. The test demonstrated 100 percent specificity and runs on Ortho’s high-throughput, fully automated analyzers including its Vitros XT 7600 integrated system, Vitros 3600 immunodiagnostic system, Vitros 5600 integrated system, and it will soon be available on Vitros ECi/ECiQ immunodiagnostic systems.

Thermo Fisher, Janssen to co-develop cancer CDx

May 2020—Thermo Fisher Scientific has signed an agreement with Janssen Biotech to co-develop a companion diagnostic in oncology. The diagnostic will support clinical trial enrollment worldwide.

Horizon CHOsource platform

May 2020—Horizon Discovery Group announced its cGMP-compliant CHOsource platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases. Horizon’s Chinese hamster ovary cells delivered high yields of monoclonal antibody for LAG-3 immunotherapy, the company reported in a press statement, enabling Immutep and Batavia Biosciences to reach a milestone in the preclinical development of the compound.

New books: pathology art, atlas, endocrine guide

April 2020—Sylvia L. Asa, MD, PhD, consultant in endocrine pathology, University Hospitals Cleveland Medical Center and University Health Network Toronto, and professor of pathology, Case Western Reserve University, served as an editor of two recently published books related to pathology and is a coauthor of the first book in series five of the AFIP Atlas of Tumor and Non-Tumor Pathology series. Dr. Asa showcased these books at this year’s USCAP meeting in Los Angeles. Art Gallery of Pathology (ARP Press), created by Tim-Rasmus Kiehl, MD, and edited by Dr. Asa, explores the use of human pathology samples as they are used to create art. Dr. Kiehl worked as a neuropathologist at University Health Network in Toronto.

Randox STI assay gets CE mark

April 2020—Randox announced that its Randox STI assay has received the CE mark. The multiplex assay detects 10 STIs, including co-infections, from a single patient sample. It tests simultaneously for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Treponema pallidum, HSV-1, HSV-2, Haemophilus ducreyi, Mycoplasma hominis, and Ureaplasma urealyticum.

BD, Babson to enable blood collection in retail settings

April 2020—Becton Dickinson and Babson Diagnostics, a diagnostic blood testing company, announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies. BD’s capillary specimen collection devices, in development, are designed to enable the collection of laboratory-quality specimens without the need to access a vein and are for use in health care settings without a trained phlebotomist, such as retail pharmacies, physician offices, urgent care centers, and skilled nursing facilities. Babson’s offerings include proprietary automated sample handling and analytical technologies, which are also in development.

Leica Biosystems digital pathology scanner

April 2020—Leica Biosystems launched the Aperio GT 450, its next-generation digital pathology scanner. The research-use-only Aperio GT 450 offers continuous rack loading with priority scanning and takes 32 seconds to scan a 15 mm × 15 mm tissue area on a pathology slide at 40× magnification with a throughput of 81 slides per hour. The system’s slide racks are compatible with other Leica Biosystems products.

FDA authorizes marketing of Fragile X syndrome dx

April 2020—The FDA authorized the marketing of AmplideX Fragile X Dx and Carrier Screen Kit (Asuragen). It is the first test, according to the FDA, to detect Fragile X syndrome, the most common known cause of inherited developmental delay and intellectual disability. Additionally, this test is intended for use in adults who may be carriers of genetic alterations in the FMR1 gene.

FDA approves neratinib for metastatic HER2+ breast cancer

April 2020—The FDA approved neratinib (Nerlynx, Puma Biotechnology) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting.

New England Tissue Issue joins ProPath

April 2020—ProPath announced that New England Tissue Issue, a dermatopathology practice in Fall River, Mass., has joined the ProPath family of companies. The partnership will allow 8 million patients from NETI’s catchment area in-network access to ProPath’s esoteric testing.

MARKETPLACE

TRENDING